The potential growth difference for the age-related macular degeneration (AMD) therapeutics market between 2020 and 2025 is USD 7.92 bn. To get the exact yearly growth variance and the Y-O-Y growth rate, Talk to our analyst.
Key Market Dynamics:
- Market Driver
- Market Challenges
The high prevalence of AMD is one of the key market drivers. This is attributed to the presence of high-risk factors for developing the condition. Risk factors such as aging, smoking, high cholesterol, and high blood pressure are the major contributors to the development of AMD. The prevalence rate of wet AMD is 10%-15% and that of dry AMD is around 85%-90%. Despite the high prevalence, no approved therapies are available in the market for the treatment of dry AMD. The high prevalence, along with the significant unmet medical need of dry AMD, is expected to drive market growth during the forecast period.
However, factors such as lack of approved therapies for dry AMD will challenge market growth. The lack of approved therapies for AMD has compelled pharmaceutical companies to actively investigate new drugs for the treatment of the condition. Companies are entering into collaborations, which will improve the development process and raise investments in research activities. For instance, in October 2020, Gemini Therapeutics and FS Development Corp. entered into a merger agreement. This agreement will help in the development of advanced treatments or therapeutics for AMD. Such factors are expected to drive market growth during the forecast period.
To learn about additional key drivers, trends, and challenges available with Technavio. Read our FREE Sample Report right now!
Market Segmentation
By type, the age-related macular degeneration (AMD) therapeutics market report is segmented into wet AMD and dry AMD. The wet AMD segment will have significant market share growth during the forecast period. People with wet AMD can see a dark spot in the center of their vision due to blood or fluid under the macula. It impacts approximately 1.1 million people in the US and is a leading cause of blindness in people aged 60 and above. The growth of this segment is primarily driven by the increasing use of vascular endothelial growth factor (VEGF) inhibitors, which are largely used for the treatment of wet AMD.
By geography, the market has been segmented into North America, Europe, Asia, and ROW. North America will be the leading region with 40% of the market's growth during the forecast period. The US and Canada are the key countries for the age-related macular degeneration (AMD) therapeutics market in North America.
View our sample report for additional insights into the contribution of all the segments, and regional opportunities in the report.
Some Companies Mentioned
- Alkeus Pharmaceuticals Inc.
- Allegro Ophthalmics LLC
- Amgen Inc.
- Apellis Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Outlook Therapeutics Inc.
- Reliance Industries Ltd.
- To gain access to more vendor profiles with their key offerings available with Technavio, Click Here
Related Reports:
Stem Cell Banking Market by Type and Geography - Forecast and Analysis 2021-2025
Microbial Products Market by Application and Geography - Forecast and Analysis 2022-2026
Age-Related Macular Degeneration (AMD) Therapeutics Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 11.96% |
Market growth 2021-2025 |
USD 7.92 billion |
Market structure |
Fragmented |
YoY growth (%) |
10.80 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 40% |
Key consumer countries |
US, Canada, Germany, China, and UK |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Alkeus Pharmaceuticals Inc., Allegro Ophthalmics LLC, Amgen Inc., Apellis Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics Inc., and Reliance Industries Ltd. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Wet AMD - Market size and forecast 2020-2025
- Dry AMD - Market size and forecast 2020-2025
- Market opportunity by Type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Alkeus Pharmaceuticals Inc.
- Allegro Ophthalmics LLC
- Amgen Inc.
- Apellis Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Outlook Therapeutics Inc.
- Reliance Industries Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article